Angiogenesis inhibitor targeting both VEGFR and Tie2 like cabozantinib, regorafenib and sorafenib have also shown efficacy in the treatment of renal cancer, thyroid cancer, gastrointestinal stromal tumor and liver cancer [26]. This evidence concerns the gene TEK and renal carcinoma.